Macrophages have recently gained attention in systemic lupus erythematosus (SLE) pathogenesis for their role in the anti-inflammatory clearance of apoptotic cells. The M1/M2 polarization of macrophages improves efferocytic capability. Peroxisome proliferator-activated receptor γ is proposed to function in the expansion of the M2 subpopulation. Pioglitazone is a peroxisome proliferator-activated receptor γ agonist with a variety of anti-inflammatory effects. In this paper, we investigated the ex vivo alterations of monocyte-derived macrophages of 15 newly diagnosed SLE patients and 10 normal subjects triggered by apoptotic cells among SLE patients following pioglitazone treatment. The phagocytosis capacity of macrophages and M1/M2 polarization (CD86/CD163) was evaluated. The supernatants were also analyzed for the expression of interleukin (IL)-10, IL-12, transforming growth factor β1 and TNF-α. The mRNA expression of IL-1β and mannose receptor C-type 1 were also quantified among treated and non-treated monocyte-derived macrophages. We found that efferocytosis is defective among monocyte-derived macrophages of SLE patients and might be a major underlying mechanism involved in the sustained inflammation. Pioglitazone could enhance alternative activation of monocyte-derived macrophages and consequently immunomodulation in these patients.
AbsherDMLiXWaiteLLet al.Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. PLoS Genet2013; 9: e1003678–e1003678.
2.
PetriMOrbaiAMAlarcónGSet al.Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64: 2677–2686.
3.
Lech M, Anders H-J. The pathogenesis of lupus nephritis. J Am Soc Nephrol 2013: 24:1357–1366.
4.
Majai G, Kiss E, Tarr T, et al. Decreased apopto-phagocytic gene expression in the macrophages of systemic lupus erythematosus patients. Lupus 2013: 23: 133–145.
5.
AndradeFCasciola-RosenLRosenA. Apoptosis in systemic lupus erythematosus: clinical implications. Rheum Dis Clin North Am2000; 26: 215–227.
6.
SicaAMantovaniA. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest2012; 122: 787–795.
7.
MantovaniASicaASozzaniSAllavenaPVecchiALocatiM. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol2004; 25: 677–686.
8.
VandivierRWHensonPMDouglasIS. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest2006; 129: 1673–1682.
KornsDFraschSCFernandez-BoyanapalliRHensonPMBrattonDL. Modulation of macrophage efferocytosis in inflammation. Macrophages Inflamm Resol2011; 2: 62–62.
11.
MartinezFOGordonS. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep2014; 6: 12703–12703.
12.
MosserDMEdwardsJP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol2008; 8: 958–969.
13.
BouhlelMADerudasBRigamontiEet al.PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab2007; 6: 137–143.
14.
Chinetti-GbaguidiGStaelsB. Macrophage polarization in metabolic disorders: functions and regulation. Curr Opin Lipidol2011; 22: 365–372–365–372.
15.
CariouBCharbonnelBStaelsB. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab2012; 23: 205–215.
16.
TanEMCohenASFriesJFet al.The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
17.
VissersMCJesterSAFantoneJC. Rapid purification of human peripheral blood monocytes by centrifugation through Ficoll-Hypaque and Sepracell-MN. J Immunol Methods1988; 110: 203–207.
18.
Saghaeian-JaziMMohammadiSSedighiS. Culture and differentiation of monocyte derived macrophages using human serum: an optimized method. Zahedan J Res Med Sci2016; 18: e7362–e7362.
19.
MemarianANourizadehMMasoumiFet al.Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia. Tumor Biol2013; 34: 531–542.
20.
WayKJDinhHKeeneMRet al.The generation and properties of human macrophage populations from hemopoietic stem cells. J Leukoc Biol2009; 85: 766–778.
21.
Casciola-RosenLAAnhaltGRosenA. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med1994; 179: 1317–1330.
22.
DenholmEMStankusGP. Differential effects of two fluorescent probes on macrophage migration as assessed by manual and automated methods. Cytometry1995; 19: 366–369.
23.
WangYFuYXueSet al.The M2 polarization of macrophage induced by fractalkine in the endometriotic milieu enhances invasiveness of endometrial stromal cells. Int J Clin Exp Pathol2014; 7: 194–203.
24.
MemarianAHojjat-FarsangiMAsgarian-OmranHet al.Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia. Leuk Lymphoma2009; 50: 2061–2070.
25.
PradoCde PazBGómezJLópezPRodríguez-CarrioJSuárezA. Glucocorticoids enhance Th17/Th1 imbalance and signal transducer and activator of transcription 3 expression in systemic lupus erythematosus patients. Rheumatology2011; 50: 1794–1801.
26.
ChangHYLeeH-NKimWSurhY-J. Docosahexaenoic acid induces M2 macrophage polarization through peroxisome proliferator-activated receptor γ activation. Life Sci2015; 120: 39–47.
27.
AliMHeyobKRogersLK. DHA Suppresses primary macrophage inflammatory responses via Notch 1/Jagged 1 signaling. Sci Rep2016; 6: Article number (22276)–Article number (22276).
28.
ZhaoDZhuZLiDXuRWangTLiuK. Pioglitazone suppresses CXCR7 expression to inhibit human macrophage chemotaxis through peroxisome proliferator-activated receptor gamma. Biochemistry2015; 54: 6806–6814.
29.
ZhuWYanHLiSNieWFanFZhuJ. PPAR-γ agonist pioglitazone regulates dendritic cells immunogenicity mediated by DC-SIGN via the MAPK and NF-κB pathways. Int Immunopharmacol2016; 41: 24–34.
30.
AprahamianTRBonegioRGWeitznerZGharakhanianRRifkinIR. Peroxisome proliferator-activated receptor gamma agonists in the prevention and treatment of murine systemic lupus erythematosus. Immunology2014; 142: 363–373.
31.
ZhaoWBerthierCCLewisEEMcCuneWJKretzlerMKaplanMJ. The peroxisome-proliferator activated receptor-γ agonist pioglitazone modulates aberrant T cell responses in systemic lupus erythematosus. Clin Immunol2013; 149: 119–132.
32.
BijlMReefmanEHorstGLimburgPCKallenbergCG. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis2006; 65: 57–63.
33.
ReefmanEHorstGNijkMTLimburgPCKallenbergCGBijlM. Opsonization of late apoptotic cells by systemic lupus erythematosus autoantibodies inhibits their uptake via an Fcγ receptor-dependent mechanism. Arthritis Rheum2007; 56: 3399–3411.
34.
Garcia-BatesTMBagloleCJBernardMPMurantTISimpson-HaidarisPJPhippsRP. Peroxisome proliferator-activated receptor γ ligands enhance human B cell antibody production and differentiation. J Immunol2009; 183: 6903–6912.
35.
MurrayPJAllenJEBiswasSKet al.Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity2014; 41: 14–20.
36.
SatohNShimatsuAHimenoAet al.Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients effect of pioglitazone. Diabetes Care2010; 33: e7–e7.
37.
JablonskiKAAmiciSAWebbLMet al.Novel markers to delineate murine M1 and M2 macrophages. PloSOne2015; 10: e0145342–e0145342.
38.
KimHYLeeHJChangY-Jet al.Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat Med2014; 20: 54–61.
